Objective:To explore the easily applicable indicators of practical value to evaluate the prognosis of acute respiratory distress syndrome（ARDS）.Methods:Blood and biochemical tests and bloodgas analyses were performe...Objective:To explore the easily applicable indicators of practical value to evaluate the prognosis of acute respiratory distress syndrome（ARDS）.Methods:Blood and biochemical tests and bloodgas analyses were performed upon entry into the ICUs,12 h,24 h,48 h and 72 h after that in 72 ARDS patients（who were admitted to the ICUs of our hospital from January 2000 to December 2009）.Then APACHEⅡscores were achieved by combining relevant physiological parameters and laboratory results.Results:There was a statistical difference between the death group and survival group at different time points upon entering the ICUs in terms of APACHEⅡscore, alveolar-arterial oxygen difference and arterial blood lactate clearance rate.PaO<sub>2</sub>/FiO<sub>2</sub> values were recorded to be statistically different between the death group and survival group 24 h,48 h and 72 h,respectively after entry into the ICUs.In addition,registered linear regression existed between APACHEⅡscore,alveolar-arterial oxygen difference or PaO<sub>2</sub>/FiO<sub>2</sub> value and time. APACHEⅡscore 24 h and 72 h after entering ICUs predicted mortality with an area under the ROC curve（AUC） standing respectively at 0.919 and 0.9SS.Arterial blood lactate clearance rate 12 h, 24 h,48 h and 72 h after entering ICUs predicted mortality with an area under the ROC curve （AUC） at 0.918,0.918,0.909 and 0.991,respectively.Conclusions:APACHEⅡscore applied in combination with arterial blood lactate clearance rate is of clinical significance in assessing the prognosis of ARDS patients.展开更多
目的探讨气管内滴入不同布地奈德合剂联合经鼻持续气道正压(NCPAP)对呼吸窘迫综合征(RDS)的早期疗效差异。方法按纳入标准随机将RDS高危早产儿91例(预防RDS28例,诊断RDS治疗63例)分为观察组(气管内滴入沐舒坦-布地奈德混合剂)和对照组(...目的探讨气管内滴入不同布地奈德合剂联合经鼻持续气道正压(NCPAP)对呼吸窘迫综合征(RDS)的早期疗效差异。方法按纳入标准随机将RDS高危早产儿91例(预防RDS28例,诊断RDS治疗63例)分为观察组(气管内滴入沐舒坦-布地奈德混合剂)和对照组(气管内滴入固尔苏-布地奈德混合剂),均予NCPAP通气,比较预防病例RDS发生率和RDS治疗病例PaO2/FiO2改善情况。结果两组均无RDS新发病例;两组RDS病例治疗前及治疗后6、12 h PaO2/FiO2无差异(P>0.05),治疗后1小时观察组比对照组低(P<0.01)。结论两种布地奈德混合剂及早气管内滴入均能有效预防RDS、改善RDS肺功能,但观察组显效慢。展开更多
基金sponsored by Guangdong Science and Technology Project(No:2009B03081118)
文摘Objective:To explore the easily applicable indicators of practical value to evaluate the prognosis of acute respiratory distress syndrome（ARDS）.Methods:Blood and biochemical tests and bloodgas analyses were performed upon entry into the ICUs,12 h,24 h,48 h and 72 h after that in 72 ARDS patients（who were admitted to the ICUs of our hospital from January 2000 to December 2009）.Then APACHEⅡscores were achieved by combining relevant physiological parameters and laboratory results.Results:There was a statistical difference between the death group and survival group at different time points upon entering the ICUs in terms of APACHEⅡscore, alveolar-arterial oxygen difference and arterial blood lactate clearance rate.PaO<sub>2</sub>/FiO<sub>2</sub> values were recorded to be statistically different between the death group and survival group 24 h,48 h and 72 h,respectively after entry into the ICUs.In addition,registered linear regression existed between APACHEⅡscore,alveolar-arterial oxygen difference or PaO<sub>2</sub>/FiO<sub>2</sub> value and time. APACHEⅡscore 24 h and 72 h after entering ICUs predicted mortality with an area under the ROC curve（AUC） standing respectively at 0.919 and 0.9SS.Arterial blood lactate clearance rate 12 h, 24 h,48 h and 72 h after entering ICUs predicted mortality with an area under the ROC curve （AUC） at 0.918,0.918,0.909 and 0.991,respectively.Conclusions:APACHEⅡscore applied in combination with arterial blood lactate clearance rate is of clinical significance in assessing the prognosis of ARDS patients.
文摘目的探讨气管内滴入不同布地奈德合剂联合经鼻持续气道正压(NCPAP)对呼吸窘迫综合征(RDS)的早期疗效差异。方法按纳入标准随机将RDS高危早产儿91例(预防RDS28例,诊断RDS治疗63例)分为观察组(气管内滴入沐舒坦-布地奈德混合剂)和对照组(气管内滴入固尔苏-布地奈德混合剂),均予NCPAP通气,比较预防病例RDS发生率和RDS治疗病例PaO2/FiO2改善情况。结果两组均无RDS新发病例;两组RDS病例治疗前及治疗后6、12 h PaO2/FiO2无差异(P>0.05),治疗后1小时观察组比对照组低(P<0.01)。结论两种布地奈德混合剂及早气管内滴入均能有效预防RDS、改善RDS肺功能,但观察组显效慢。
